Introduction
The identi®cation of the molecular events that underlie the development of human tumours is a major challenge in the design of improved strategies in the prevention, management and cure of these diseases. In this context, the role of aberrantly regulated protein tyrosine kinases (PTKs) in human tumour development has been the subject of much investigation. In studies on breast tumours, the total PTK activity in extracts of malignant tissue has been reported to be signi®cantly greater than in extracts from benign or normal mammary tissue and increased PTK activity in cytosolic extracts has been reported to be correlated with decreased disease free and overall survival (Hennipman et al., 1989; Ottenho-Kal et al., 1992; Bolla et al., 1993; Lower et al., 1993; Romain et al., 1994) .
The activities of speci®c PTKs have been implicated in breast tumour development. High levels of expression of the related epidermal growth factor receptor and c-erbB-2 PTKs in 35 ± 50% and 20 ± 30% of breast tumours respectively have been found to be associated with poor prognosis (Sainsbury et al., 1987; Slamon et al., 1987 Slamon et al., , 1989 Harris et al., 1989; Grimaux et al., 1989; Toi et al., 1989; Nicholson et al., 1991; Gullick et al., 1991; Paterson et al., 1991; Gusterson et al., 1992) . Further, studies in animal model systems have supported the hypothesis that elevated expression of such molecules can predispose to tumour development. For example, expression of proto-oncogenic neu (rat c-erbB-2) in the mammary epithelium of transgenic mice results in the focal development of tumours with metastatic potential (Guy et al., 1992) . However, it may not be valid to draw direct analogies between human breast tumours and proto-oncogenic neu induced tumours in mice, since further studies in the latter system have revealed that tumourigenesis is associated with the acquisition of alterations to the neu coding sequence , whereas comparable c-erbB-2 coding mutations have yet to be associated with the development of human breast tumours.
The tyrosine kinase activity of the product of the c-src proto-oncogene has been found to be elevated in human breast tumours (Jacobs and Rubsamen, 1983; Rosen et al., 1986; Ottenho-Kal et al., 1992) . Transgenic mouse models have provided further indirect support for c-src having an important role in breast tumour development. Moreover, activated c-src has been found to associate with Neu in neu induced mammary tumours . Furthermore, c-src is required for mammary tumour induction by the polyomavirus middle T oncogene (Guy et al., 1994) , and expression of mutationally activated c-src in the mammary epithelium causes developmental abnormalities, hyperplasia, and a predisposition to neoplasia (Webster et al., 1995) .
We have recently described the cDNA cloning of brk from a metastatic human breast cancer and human breast carcinoma cell lines (Mitchell et al., 1994) . The predicted BRK protein contains SH3, SH2 and PTK catalytic domains; this arrangement and amino acid sequence similarity allies BRK most closely with the SRC family of PTKs. However, BRK diers from the SRC-like kinases in several respects, most notably in its lack of an N-terminal extension and consensus sequences for fatty acylation and membrane association. BRK expression can partially transform ®broblasts in a process that is regulated in a manner distinct from transformation by SRC and expression of BRK in mammary epithelial cells potentiates both their anchorage independent proliferation and their mitogenic response to epidermal growth factor (Kamalati et al., 1996b) . These ®ndings imply a role for BRK in growth regulation, and potentially tumour development.
To date, brk mRNA expression has been detected in human breast tumour tissue and tumour cell lines, however the low mRNA levels have hindered more detailed studies. This report describes the results obtained using newly isolated monoclonal antibodies to study the expression of BRK protein in relation to the development of human breast tumours.
Results

Characterisation of a monoclonal antibody speci®c for BRK
Monoclonal antibodies recognising BRK were isolated by immunising rats with bacterially expressed protein (Kamalati et al., 1996b) . To investigate the speci®city of one of these (ICR 100), whole cell lysates of HB4a human mammary epithelial cells transfected with either a brk cDNA expression vector or empty vector only (Kamalati et al., 1996b) were analysed by Western blotting. ICR 100 recognised a single band of approximately 50 kDa in HB4a+brk lysates ( Figure  1 ) while HB4a+empty vector lysates revealed a faint 50 kDa band only after a much longer exposure. A protein migrating with the same mobility as that encoded by the transfected brk cDNA was detected in T-47D breast carcinoma cells, the original source of the brk cDNA (Mitchell et al., 1994) . In order to address the basis of the dierential expression of BRK protein, an RNase protection assay was performed. A speci®c protected fragment indicative of brk mRNA expression was detected using T-47D, but not Cal51 RNA (Figure 4 ).
BRK expression in breast derived cell lines
Expression of BRK in mammary tissue in vivo
Because BRK was expressed at appreciable levels in a high proportion of breast carcinoma cell lines (approximately 70%), but not in non-transformed Figure 5b ). BRK expression was quanti®ed by Western blotting of lysates from normal breast tissue and breast tumours and the results were normalised to the cytokeratin 18 loading control (Table 1) . Of 41 tumours, 27% over expressed BRK by ®vefold or more (61% over expressed by 26 or more), the highest level detected being equivalent to 436 over expression.
BRK expression was undetectable in eight fibroadenoma samples (Figure 6 ).
BRK expression in relation to cell proliferation
A possible explanation for the higher levels of BRK expression detected in breast tumours was that it was indicative of dierent cell cycle pro®les, or that it was related to the rate of cell proliferation.
T-47D carcinoma cells were sorted into three cell cycle phases, G1, S and G2, by¯uorescence activated cell sorting based on DNA content visualised by propidium iodide staining. Western blotting revealed no dierences in BRK levels in any of the phases compared with a sample of unsorted asynchronously proliferating cells (Figure 7) .
T-47D cells were cultured in medium containing high concentrations of serum components, or medium with low serum and stripped of potential oestrogenic components, thus generating populations proliferating at rates that diered by approximately twofold. Western blotting revealed that BRK expression levels were indistinguishable in the two populations (Figure 8 ).
Discussion
We have previously described the cDNA cloning of brk from breast carcinoma cell lines, and the expression of its mRNA in a small panel of primary breast carcinomas (Mitchell et al., 1994) . In this study, BRK protein expression has been found to be elevated frequently in breast tumour tissue and tumour derived cell lines, when compared with normal mammary tissue and a panel of non transformed mammary epithelial cell lines respectively. The latter (except HB1a) were immortalized from cultures of primary luminal Figure 4 Dierential expression of the brk mRNA. RNase protection was performed with a brk probe on RNA puri®ed from yeast, CAL51 carcinoma cells or T-47D carcinoma cells. A probe for GAPDH was used to con®rm the integrity of the CAL51 and T-47D RNA epithelial cells puri®ed from normal human mammary tissue (Stamps et al., 1994) , and retain many features of normal mammary luminal epithelial cells (Kamalati et al., 1996a) . Of these, the best characterised are the HB4a cells. Their growth characteristics are very similar to normal mammary luminal cells, and since luminal cells are the likely precursors of the majority of breast carcinomas (Taylor-Papadimitriou and Lane, 1987) , they are a good model system in which to study the functions of molecules implicated in breast tumour development (Kamalati et al., 1996b) . The low or undetectable levels of BRK in this panel of cell lines contrasted with the much higher expression in the majority of the breast carcinoma cell lines investigated, suggesting that BRK expression in mammary epithelial cells may be an important feature of the breast carcinoma phenotype. The clinical relevance of this observation was supported by the ®nding that BRK levels were elevated in many breast tumours (but not benign lesions) in vivo. The degree of over expression in breast tumours varied widely, with the highest level detected being 43-fold above the consistently low level found in normal mammary tissue. Approximately two thirds of breast tumours had elevated BRK levels and 27% of tumours over expressed BRK by ®ve fold or more. Therefore, elevated BRK expression is a feature of a signi®cant proportion of breast tumours. BRK expression was not found to be related to the cell cycle position or overall rate of proliferation of T-47D breast carcinoma cells; it is thus unlikely that the dierential expression seen in vivo is a consequence of dierential growth rates in normal and malignant breast epithelium. In breast carcinoma cell lines that over express c-erbB-2, the elevated levels have been reported to be due to both gene ampli®cation and increased rates of gene transcription (Bosher et al., 1996) . In the cell lines investigated here, brk mRNA levels re¯ected protein expression and, since amplification of the brk gene has not been detected in the panel of carcinoma cell lines used here (data not shown), it is probable that BRK mRNA transcription or stability is augmented in breast tumours. Future studies on the regulation of BRK expression will be required to clarify this. Expression of BRK in ®broadenomas. Lysates were prepared from reduction mammoplasty (N), ®broadenoma (F) and carcinoma (T) samples and Western blotted. Protein integrity and epithelial cell contribution were determined using an antibody to cytokeratin 18, and BRK was detected with antibody ICR100
In recent studies, we have found that BRK expression in ®broblasts and human mammary epithelial cells resulted in increased anchorage independent proliferation. Further, the epithelial cells expressing BRK acquired a potentiated mitogenic response to epidermal growth factor (EGF) (Kamalati et al., 1996b) . Since the expression of EGF like peptides may have a role in the pathogenesis of human breast cancer (reviewed by Normanno et al., 1994) , it is possible that BRK expression actively contributes to the malignant phenotype in many breast cancers through its over expression and consequent conferral of growth advantage. Future studies will address this hypothesis, with the view of determining whether BRK could be a target for novel tumour therapies.
Materials and methods
Western blotting
Lysates, made in SDS ± PAGE sample buer from pulverised frozen tissues or cultured cells, were resolved by SDS ± PAGE and electrophoretically transferred tò Hybond-ECL' membranes (Amersham). Blots were blocked in PBS/10% w/v non-fat dried milk. Antibody incubations were in PBS/10% v/v FCS, and washes were in PBS/0.1% v/v Tween-20. The ICR100 rat monoclonal antibody to BRK has been described elsewhere (Kamalati et al., 1996b) Figure 8 BRK expression in relation to cell proliferation rate. T-47D carcinoma cells were cultured in phenol red containing medium with 10% serum (+) or phenol red free medium with 2% charcoal stripped serum (7). Cell numbers were determined at days 3, 5 and 7 of culture (a). Lysates of the cells at these times were Western blotted with antibody ICR100 and anti cytokeratin 18 to compare BRK expression levels (b)
Figure 7 Expression of BRK through the cell cycle. Lysates were prepared from unsorted proliferating T-47D carcinoma cells (U), and from T-47D cells sorted by DNA content into populations at G1, S and G2 of the cell cycle. Western blot loading was normalized using an antibody to cytokeratin 18, and BRK was detected with antibody ICR100 using horseradish peroxidase conjugated rabbit antibodies to rat or mouse immunoglobulins (Dako) and`ECL' detection reagents (Amersham). For the quantitation of antigens on blots, rabbit antibodies to rat (Zymed) or mouse (Sigma) immunoglobulins were used, followed by 125 I-labelled protein A (Amersham) incubated at 1 mCi/ml. Quantitation was achieved using a Phosphorimager (Molecular Dynamics). In order to correct for blot to blot variations, all results were normalized to a sample containing both BRK and cytokeratin 18 that was included on every gel.
Cell culture
Immortalized mammary cell lines HB1a, 2a, 2c, 2d, 4a, 4b and 4c, derived as described (Stamps et al., 1994) , were cultured in RPMI 1640, 10% foetal bovine serum (FBS), hydrocortisone (5 mg/ml), cholera toxin (0.1 mg/ml) and insulin (5 mg/ml). MCF 10A (ATCC-CRL 10317) were grown in DMEM Hams F12, 5% horse serum, hydrocortisone (0.5 mg/ml), cholera toxin (0.1 mg/ml), insulin (5 mg/ml) and EGF (0.01 mg/ml). (Whitehead et al., 1983) and Cal51 (Gioanni et al., 1990) were routinely cultured in DMEM, 10% FBS.
Cell cycle analysis of protein expression
Exponentially growing T-47D cells were harvested by trypsinisation, washed once in PBS and ®xed by resuspension in ice cold 70% ethanol. Samples were stored overnight at 48C. Cells were pelleted by centrifugation, resuspended in PBS, treated with RNase (100 mg/ml) and propidium iodide (20 mg/ml) and incubated at 378C for 30 min. Cells were sorted into three cell cycle phases G1, S and G2, determined by DNA content based on propidium iodide staining, using a Coulter EPICS Elite ESP (Coulter Corporation) with a Spectra Physics argon ion laser producing 200 mW of light at 488 nm. Forward, 908C light scatter and red¯uorescence greater than 630 nm were collected. To exclude clumps, cells were gated on a cytogram of red¯uorescence peak/red¯uorescence area (Ormerod, 1994) . Sorted cells were pelleted by centrifugation, washed in PBS and lysed in SDS sample buer.
Dierential proliferation rates in T-47D cells
T-47D were seeded at 10 5 cells per well in 6-well multiwell plates in DMEM, 10% FBS. After 24 h, medium was replaced with either fresh DMEM, 10% FBS or phenol red free DMEM, 2% charcoal stripped-FBS. Medium was replaced every 48 h. After 3, 5 and 7 days, triplicate wells were trypsinized and cell number determined using a Coulter counter. One well for each time point was washed in PBS and lysed in SDS sample buer.
RNase protection
Total RNA from T-47D, CAL51 and yeast was hybridised with a 32 P labelled antisense RNA probe corresponding to bases 1049-1212 of the brk cDNA, or with an antisense GAPDH RNA probe. Ribonuclease protection was performed using reagents and protocols from the Ambion RPA II TM kit.
